Latest news, Events and Press Releases

Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.

Please direct any media inquiries to communications@curiumpharma.com

News Press releases Events Publications

Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint

28th March 2025

Curium Further Expands European Availability of Pylclari® – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients With Prostate Cancer

28th January 2025

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

19th November 2024

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

13th November 2024

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

1st October 2024

Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain

10th September 2024

Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer

17th June 2024

Curium adds the Institut Laue–Langevin reactor to global irradiation portfolio to ensure continuous supply of Lutetium-177 benefit more than 100,000 cancer patients over the next 5 years

5th June 2024

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

30th May 2024

Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

6th May 2024

Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol

8th April 2024

Curium announces first commercial doses in the Netherlands of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer

19th March 2024

1 2 3